Published :
Tables : 64
Figures : 42
Category : Healthcare
No. of Pages : 228
Report Code : HC-U3412
Immunotherapy Drugs Market is estimated to value over USD 270 billion by 2027 end with a CAGR of over 10% during the forecast period 2020 to 2027. The increasing occurrences of targeted diseases, rising insistence for biosimilars and monoclinal antibodies, rising acceptance of immunotherapy drugs over traditional drugs are some of the key factors responsible for the immunotherapy drugs market growth. Conversely, side-effects of these drugs, issues related to the timeline and complexities in manufacturing and a high rate of attrition in the product development cycle shall impede the proliferation of the market. Major players included in the Immunotherapy Drugs Market: • F. Hoffmann-La Roche Ltd. • Pfizer Inc. • Merck & Co • Novartis International AG • Johnson & Johnson • Sanofi • GlaxoSmithKline Plc • Amgen Inc. • Abbvie Inc. • Boehringer Ingelheim • AstraZeneca • Immatics Biotechnologies • Biontech SE • Genmab • Gilead Sciences • NBE Therapeutics • Teva Pharmaceuticals • Bayer • Bristol-Myers Squibb • Eli Lilly And Company • Incyte Corporation (Note: The list of the major players will be updated with the latest market scenario and trends) Immunotherapy Drugs Market Segmentation: By Type • Checkpoint Inhibitors • Adult Vaccines • Interleukins • Monoclonal Antibodies • Interferons • Alpha And Beta • Others By Therapy Area • Cancer • Infectious Diseases • Autoimmune & Inflammatory Diseases By End User • Clinics • Hospitals • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is categorised into type, therapy area, end user and region. The type segment is fragmented into check point inhibitors, monoclonal antibodies, interleukins and interferons. The monoclonal antibodies segment held the largest immunotherapy drugs market share owing to fewer side effects and high specificity, rising emphasis on personalised medicines, increased prevalence of targeted diseases and growing initiatives by key market players. The therapy area segment is classified into cancer, infectious diseases and autoimmune & inflammatory diseases. Cancer segment led the market in 2019 and this can be credited to rising incidence of cancer, favourable reimbursement scenarios for oncology. The end user segment is diversified into clinics, hospitals and other end users. The hospital segment is predicted to dominate the market owing to the increased hospital expenditure for immunotherapies. Regional Analysis: The North America region is anticipated to dominate the market owing to rising incidences of autoimmune diseases and cancer, rising insistence for safe therapies, growing FDA approvals and favourable reimbursement scenarios. Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Immunotherapy Drugs Market By Type, By Therapy Area, By End-User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- Type launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The increasing occurrences of targeted diseases, rising insistence for biosimilars and monoclinal antibodies, rising acceptance of immunotherapy drugs over traditional drugs are some of the key factors responsible for the immunotherapy drugs market growth. Conversely, side-effects of these drugs, issues related to the timeline and complexities in manufacturing and a high rate of attrition in the product development cycle shall impede the proliferation of the market.
Major players included in the Immunotherapy Drugs Market: • F. Hoffmann-La Roche Ltd. • Pfizer Inc. • Merck & Co • Novartis International AG • Johnson & Johnson • Sanofi • GlaxoSmithKline Plc • Amgen Inc. • Abbvie Inc. • Boehringer Ingelheim • AstraZeneca • Immatics Biotechnologies • Biontech SE • Genmab • Gilead Sciences • NBE Therapeutics • Teva Pharmaceuticals • Bayer • Bristol-Myers Squibb • Eli Lilly And Company • Incyte Corporation (Note: The list of the major players will be updated with the latest market scenario and trends)
Immunotherapy Drugs Market Segmentation:
By Type • Checkpoint Inhibitors • Adult Vaccines • Interleukins • Monoclonal Antibodies • Interferons • Alpha And Beta • Others
By Therapy Area • Cancer • Infectious Diseases • Autoimmune & Inflammatory Diseases
By End User • Clinics • Hospitals • Others
By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is categorised into type, therapy area, end user and region. The type segment is fragmented into check point inhibitors, monoclonal antibodies, interleukins and interferons. The monoclonal antibodies segment held the largest immunotherapy drugs market share owing to fewer side effects and high specificity, rising emphasis on personalised medicines, increased prevalence of targeted diseases and growing initiatives by key market players. The therapy area segment is classified into cancer, infectious diseases and autoimmune & inflammatory diseases. Cancer segment led the market in 2019 and this can be credited to rising incidence of cancer, favourable reimbursement scenarios for oncology. The end user segment is diversified into clinics, hospitals and other end users. The hospital segment is predicted to dominate the market owing to the increased hospital expenditure for immunotherapies.
Regional Analysis:
The North America region is anticipated to dominate the market owing to rising incidences of autoimmune diseases and cancer, rising insistence for safe therapies, growing FDA approvals and favourable reimbursement scenarios.
Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the Immunotherapy Drugs Market By Type, By Therapy Area, By End-User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- Type launches, technological advancements, mergers and expansions
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Immunotherapy Drugs Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Immunotherapy Drugs Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Immunotherapy Drugs Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Immunotherapy Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Immunotherapy Drugs Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Checkpoint Inhibitors 7.2. Adult Vaccines 7.3. Interleukins 7.4. Monoclonal Antibodies 7.5. Interferons 7.6. Alpha And Beta 7.7. Others 8. Global Immunotherapy Drugs Market, By Therapy Area Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Cancer 8.2. Infectious Diseases 8.3. Autoimmune & Inflammatory Diseases 9. Global Immunotherapy Drugs Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Hospital 9.2. Clinics 9.3. Others 10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2020-2027 11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.3.1. Brazil 11.3.2. Venezuela 11.3.3. Argentina 11.3.4. Rest of Latin America 11.4. Market Size (USD Million) Forecast for Latin America 2020-2027 12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Switzerland 12.2.9. Rest of Western Europe 12.3. Market Size (USD Million) Forecast for Europe 2020-2027 13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Japan 13.2.2. China 13.2.3. Singapore 13.2.4. India 13.2.5. Australia and New Zealand 13.2.6. ASEAN 13.2.7. South Korea 13.2.8. Taiwan 13.2.9. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Saudi Arabia 14.2.2. UAE 14.2.3. South Africa 14.2.4. Egypt 14.3. Market Size (USD Million) Forecast for MEA 2020-2027 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 15.1. F. Hoffmann-La Roche Ltd. 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. Pfizer Inc. 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. Merck & Co 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. Novartis International AG 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 Johnson & Johnson 15.5.1. Company Overview 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 Sanofi 15.6.1. Company Overview 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. GlaxoSmithKline Plc 15.7.1. Company Overview 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. Amgen Inc. 15.8.1. Company Overview 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. AbbVie Inc. 15.9.1. Company Overview 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10. Boehringer Ingelheim 15.10.1. Company Overview 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 15.11. AstraZeneca 15.11.1. Company Overview 15.11.2. Product Portfolio 15.11.3. SWOT Analysis 15.11.4. Financial Overview 15.11.5. Strategic Overview 15.12. Immatics Biotechnologies 15.12.1. Company Overview 15.12.2. Product Portfolio 15.12.3. SWOT Analysis 15.12.4. Financial Overview 15.12.5. Strategic Overview 15.13. Biontech SE 15.13.1. Company Overview 15.13.2. Product Portfolio 15.13.3. SWOT Analysis 15.13.4. Financial Overview 15.13.5. Strategic Overview 15.14. Genmab 15.14.1. Company Overview 15.14.2. Product Portfolio 15.14.3. SWOT Analysis 15.14.4. Financial Overview 15.14.5. Strategic Overview 15.15. Gilead Sciences 15.15.1. Company Overview 15.15.2. Product Portfolio 15.15.3. SWOT Analysis 15.15.4. Financial Overview 15.15.5. Strategic Overview 15.16. NBE Therapeutics 15.16.1. Company Overview 15.16.2. Product Portfolio 15.16.3. SWOT Analysis 15.16.4. Financial Overview 15.16.5. Strategic Overview 15.17. Teva Pharmaceuticals 15.17.1. Company Overview 15.17.2. Product Portfolio 15.17.3. SWOT Analysis 15.17.4. Financial Overview 15.17.5. Strategic Overview 15.18. Bayer 15.18.1. Company Overview 15.18.2. Product Portfolio 15.18.3. SWOT Analysis 15.18.4. Financial Overview 15.18.5. Strategic Overview 15.19. Bristol-Myers Squibb. 15.19.1. Company Overview 15.19.2. Product Portfolio 15.19.3. SWOT Analysis 15.19.4. Financial Overview 15.19.5. Strategic Overview 15.20. Eli Lilly And Company 15.20.1. Company Overview 15.20.2. Product Portfolio 15.20.3. SWOT Analysis 15.20.4. Financial Overview 15.20.5. Strategic Overview 15.21. Incyte Corporation 15.21.1. Company Overview 15.21.2. Product Portfolio 15.21.3. SWOT Analysis 15.21.4. Financial Overview 15.21.5. Strategic Overview 16. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics